Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Changan Granules for diarrhea‑predominant irritable bowel syndrome
CTR20202508Phase 2Completed
- Sponsor
- SHUTCM Yuanchuang Technology
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Changan Granules in Diarrhea-predominant irritable bowel syndrome (IBS-D), sponsored by SHUTCM Yuanchuang Technology. Started Dec 2020; status: completed.
02
Drugs
Changan Granules
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on CTR20202508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202508.